A multi-slice recording system for stable late phase hippocampal long-term potentiation experiments

Kroker, Katja S.; Rosenbrock, Holger; Rast, Georg

doi:10.1016/j.jneumeth.2010.11.006

Cited by 16 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The slices were transferred to integrated brain slice chambers as described previously (Kroker et al, 2011) and continuously superfused (2.5 mL·min −1 , room temperature) with the same ACSF used for the recovery phase, except with 1.2 mM of magnesium sulfate (regular ACSF). fEPSPs were recorded from layer V of the prelimbic and infralimbic PFC and evoked by single electrical stimulus pulses (100 μs in duration, every 30 s) of the superficial layers II–III, delivered through a monopolar stimulating electrode.…”

Section: Methodsmentioning

confidence: 99%

Targeting the dopamine D₁ receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

Pekcec

Schülert

Stierstorfer

et al. 2018

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

Background and PurposeInsufficient prefrontal dopamine 1 (D1) receptor signalling has been linked to cognitive dysfunction in several psychiatric conditions. Because the PDE1 isoform B (PDE1B) is postulated to regulate D1 receptor‐dependent signal transduction, in this study we aimed to elucidate the role of PDE1 in cognitive processes reliant on D1 receptor function.Experimental ApproachCognitive performance of the D1 receptor agonist, SKF38393, was studied in the T‐maze continuous alternation task and 5‐choice serial reaction time task. D1 receptor/PDE1B double‐immunohistochemistry was performed using human and rat prefrontal brain sections. The pharmacological activity of the PDE1 inhibitor, ITI‐214, was assessed by measuring the increase in cAMP/cGMP in prefrontal brain tissue and its effect on working memory performance. Mechanistic studies on the modulation of prefrontal neuronal transmission by SKF38393 and ITI‐214 were performed using extracellular recordings in brain slices.Key ResultsSKF38393 improved working memory and attentional performance in rodents. D1 receptor/PDE1B co‐expression was verified in both human and rat prefrontal brain sections. The pharmacological activity of ITI‐214 on its target, PDE1, was demonstrated by its ability to increase prefrontal cAMP/cGMP. In addition, ITI‐214 improved working memory performance. Both SKF38393 and ITI‐214 facilitated neuronal transmission in prefrontal brain slices.Conclusion and ImplicationsWe hypothesize that PDE1 inhibition improves working memory performance by increasing prefrontal synaptic transmission and/or postsynaptic D1 receptor signalling, by modulating prefrontal downstream second messenger levels. These data, therefore, support the use of PDE1 inhibitors as a potential approach for the treatment of cognitive dysfunction.

show abstract

Section: Methodsmentioning

confidence: 99%

Targeting the dopamine D₁ receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

Pekcec

Schülert

Stierstorfer

et al. 2018

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Throughput is particularly important for translational research. Brain slices are extensively used for toxicological and pharmacological profiling, or to carry out candidate compound screens to discover new drugs (Fountain, Ting et al 1992, Stopps, Allen et al 2004, Kroker, Rosenbrock et al 2011, Graef, Wei et al 2013, Heinemann and Staley 2014). These experiments typically use simple interface or submerged-type perfusion and only one or two electrodes per slice for stimulation or recording.…”

Section: Introductionmentioning

confidence: 99%

“…However, a screen of a compound library may require hundreds or thousands of well-controlled experiments with replicates. Multi-slice systems have been developed to allow simultaneous, independent electrophysiological recordings from multiple brain slices (Stopps, Allen et al 2004, Kroker, Rosenbrock et al 2011, Graef, Wei et al 2013). However, these systems require the use of multiple perfusion systems, machined slice chambers and discrete micromanipulator-mounted electrodes, imposing practical limitations on the number of parallel experiments.…”

Section: Introductionmentioning

confidence: 99%

“…However, these systems require the use of multiple perfusion systems, machined slice chambers and discrete micromanipulator-mounted electrodes, imposing practical limitations on the number of parallel experiments. Slice survival in these multiple-slice systems is limited to only 7 hours, precluding longer term experiments (Kroker, Rosenbrock et al 2011). However, long term, multiple days- or weeks-long electrical recording experiments may be necessary to address disease processes or endpoints that require protein synthesis, cell proliferation or growth, or neural circuit rewiring.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perfused drop microfluidic device for brain slice culture-based drug discovery

Liu

Pan

Cheng

et al. 2016

Biomed Microdevices

View full text Add to dashboard Cite

Living slices of brain tissue are widely used to model brain processes in vitro. In addition to basic neurophysiology studies, brain slices are also extensively used for pharmacology, toxicology, and drug discovery research. In these experiments, high parallelism and throughput are critical. Capability to conduct long-term electrical recording experiments may also be necessary to address disease processes that require protein synthesis and neural circuit rewiring. We developed a novel perfused drop microfluidic device for use with long term cultures of brain slices (organotypic cultures). Slices of hippocampus were placed into wells cut in polydimethylsiloxane (PDMS) film. Fluid level in the wells was hydrostatically controlled such that a drop was formed around each slice. The drops were continuously perfused with culture medium through microchannels. We found that viable organotypic hippocampal slice cultures could be maintained for at least 9 days in vitro. PDMS microfluidic network could be readily integrated with substrate-printed microelectrodes for parallel electrical recordings of multiple perfused organotypic cultures on a single MEA chip. We expect that this highly scalable perfused drop microfluidic device will facilitate high-throughput drug discovery and toxicology.

show abstract

“…In agreement with this, a number of compounds known to cause deficits in cognition in vivo have been shown to decrease the magnitude of LTP, such as benzodiazepines (del Cerro et al 1992), muscarinic antagonists (Hirotsu et al 1989), glutamate receptor antagonists (Collingridge et al 1983;Balschun et al 1999), and dopaminergic antagonists (Kerr and Wickens 2001). All of the above experiments used traditional single-microelectrode field-potential recording, and more recently similar results have been obtained using multi-slice recording systems (Kroker et al 2011). LTP has also been recorded from hippocampal slice cultures (Collin et al 1997), which, unlike acute brain slices, can be maintained for several weeks enabling chronic exposure to compounds.…”

Section: In Vitro Electrophysiology and Cognitionmentioning

confidence: 59%

CNS Adverse Effects: From Functional Observation Battery/Irwin Tests to Electrophysiology

Fonck

Easter

Pietras

et al. 2015

Principles of Safety Pharmacology

View full text Add to dashboard Cite

This chapter describes various approaches for the preclinical assessment of drug-induced central nervous system (CNS) adverse effects. Traditionally, methods to evaluate CNS effects have consisted of observing and scoring behavioral responses of animals after drug is administered. Among several behavioral testing paradigms, the Irwin and the functional observational battery (FOB) are the most commonly used assays for the assessment of CNS effects. The Irwin and FOB are considered good first-tier assays to satisfy the ICH S7A guidance for the preclinical evaluation of new chemical entities (NCE) intended for humans. However, experts have expressed concern about the subjectivity and lack of quantitation that is derived from behavioral testing. More importantly, it is difficult to gain insight into potential mechanisms of toxicity by assessing behavioral outcomes. As a complement to behavioral testing, we propose using electrophysiology-based assays, both in vivo and in vitro, such as electroencephalograms and brain slice field-potential recordings. To better illustrate these approaches, we discuss the implementation of electrophysiology-based techniques in drug-induced assessment of seizure risk, sleep disruption, and cognitive impairment.

show abstract

A multi-slice recording system for stable late phase hippocampal long-term potentiation experiments

Cited by 16 publications

References 25 publications

Targeting the dopamine D₁ receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

Targeting the dopamine D₁ receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

Perfused drop microfluidic device for brain slice culture-based drug discovery

CNS Adverse Effects: From Functional Observation Battery/Irwin Tests to Electrophysiology

Contact Info

Product

Resources

About

A multi-slice recording system for stable late phase hippocampal long-term potentiation experiments

Cited by 16 publications

References 25 publications

Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

Perfused drop microfluidic device for brain slice culture-based drug discovery

CNS Adverse Effects: From Functional Observation Battery/Irwin Tests to Electrophysiology

Contact Info

Product

Resources

About

Targeting the dopamine D₁ receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

Targeting the dopamine D₁ receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance